^
    11ms
    A Multicenter, Open-Label Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-415S1 in Patients with Advanced Malignant Solid Tumors (ChiCTR2400093553)
    P1, N=66, Recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • HER-2 amplification • HER-2 mutation • NF1 mutation • MET mutation • KRAS G12
    |
    HMPL-415
    over2years
    A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=81, Recruiting, Hutchmed | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    HMPL-415
    over2years
    A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=81, Not yet recruiting, Hutchmed
    New P1 trial • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    HMPL-415